 |
Publisher: Peytchinski, Gospodin Iliev
ISSN: 1312 773X (Online)
Issue: 2013, vol. 19, book 1;
Subject Collection: Medicine
Page: 387-390
DOI: 10.5272/jimab.2013191.387
Published online: 01 April 2013
J of IMAB. 2013; 19(1):387-390;
SINGLE AGENT DOCETAXEL AS SECOND- LINE CHEMOTHERAPY FOR PRETREATED PATIENTS WITH RECURRENT NON- SMALL CELL LUNG CANCER
Deyan N. Davidov
Department of Chemotherapy, Oncological center, Medical University, Pleven, Bulgaria.
ABSTRACT:
Objective: Single agent Docetaxel is a standard therapy for patients with non- small cell lung cancer after the failure of platinum- containing regimens. The aim of this study was to explore the efficacy and safety of Docetaxel monotherapy as second- line chemotherapy in pretreated patient with inoperable non- small cell lung cancer. Methods: From January 2005 to May 2008 thirty- six consecutive patients with locally advanced or metastatic morphologically proven stage IIIB/ IV non- small cell lung cancer entered the study after failure of previous platinum- based regimens. Treatment schedule consist of Docetaxel 75 mg/m2 administered every three weeks with repetition after 21 days with Dexamethasone premedication. Results: Overall response rate, median time to progression and median survival was 16,6 %, 4,5 months and 5,6 months respectively. The main hematological toxicity was neutropenia. Conclusions: That data suggest that single agent Docetaxel remain reasonable choices for the chemotherapy in pretreated patients with non- small cell lung cancer.
Key words: Docetaxel, Non- small cell lung cancer, Second- line chemotherapy.
- Download FULL TEXT /PDF 576 KB/
Please cite this article as:
Davidov DN. Single Agent Docetaxel as Second- Line Chemotherapy for Pretreated Patients with Recurrent Non- Small Cell Lung Cancer. J of IMAB. 2013; 19(1):387-390. DOI: 10.5272/jimab.2013191.387.
Correspondence to: Dr. Deyan Nikolov Davidov, Department of Chemotherapy, Oncological Center, Medical University Pleven; 1, "St. Kliment Ohridsky" Str., 5000 Pleven, Bulgaria.
1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007 Mar;18(3):581-592. [PubMed] [CrossRef]
2. Jemal A, Siegel R, Ward E, Murrey T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006 Mar-Apr;56(2):106-130. [PubMed]
3. Yang P, Allen MS, Aubry MC, Wampflerm JA, Marks RS, Edell ES, et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest. 2005 Jul;128(1):452- 462. [PubMed] [CrossRef]
4. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for non- small- cell lung cancer. N Engl J Med. 2002 Jan 10;346(2):92-98. [PubMed] [CrossRef]
5. Georgoulias VA. Second- line chemotherapy in relapsing or refractory patients with non- small cell lung cancer. Lung Cancer. 2002 Dec;38 Suppl 3:61-66. [PubMed]
6. Fossella FV, Lee JS, Hong WK. Management strategies for recurrent non- small cell lung cancer. Semin Oncol. 1997 Aug;24(4):455- 462. [PubMed]
7. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O’Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non- small- cell lung cancer previously treated with platinum- based chemotherapy. J Clin Oncol. 2000 May;18(10):2095- 2103. [PubMed]
8. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207-214. [PubMed]
9. Brimdage MD, Pater JL, Zee B. Assessing the reliability of two toxicity scales: Implications for interpreting toxicity data. J Natl Cancer Inst. 1993 Jul 21;85(14):38- 48. [Pubmed] [CrossRef]
10. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 1999 Oct 7;311(7010):899-909. [PubMed] [CrossRef]
11. Bartesi F, Jacot W, Astoul P, Pujol JL. Second line treatment for advanced non- small cell lung cancer: a systematic review. Lung cancer. 2006 Feb;51(2):159-172. [PubMed] [CrossRef]
12. Gandara DR, Vokes E, Green M, Bonomi P, Devore R, Comis R, et al. Activity of docetaxel in platinum-treated non- small- cell lung cancer: Results of a phase II multicenter trial. J Clin Oncol. 2000 Jan;18(1):131-135. [PubMed]
13. Le Chevalier T. Docetaxel: meeting the challenge of non- small- cell lung cancermanagement. Anticancer drugs. 1995 Jul;6 Suppl 4:13-17. [PubMed]
14. Shepferd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O’Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000 May;18(10):2095-2103. [PubMed]
15. Fosella FV, DeVore R, Kerr RN, Crawforf J, Natale RR, Dunphy F. et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non- small- cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group, J Clin Oncol. 2000 Jun;18(12):2354- 2362. [PubMed]
Accepted for publication: 23 October 2012
Published online: 01 April 2013